N-[1-(2-Chlorophenyl)-2-1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-ylethyl]-4-methylbenzenesulfonamide

Romain Paoli-Lombardo, Nicolas Primas, Caroline Castera-Ducros, Inès

Jacquet, Pascal Rathelot, Patrice Vanelle

► To cite this version:

Romain Paoli-Lombardo, Nicolas Primas, Caroline Castera-Ducros, Inès Jacquet, Pascal Rathelot, et al.. N-[1-(2-Chlorophenyl)-2-1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-ylethyl]-4-methylbenzenesulfonamide. Molbank, 2023, 2023 (2), pp.M1633. 10.3390/m1633.1633

HAL Id: hal-04503183

https://amu.hal.science/hal-04503183v1

Submitted on 13 Mar 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Short Note

N-[1-(2-Chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide

Romain Paoli-Lombardo <fnref n="1" />, Nicolas Primas <fnref n="1" />,<fnref n="2" />,* ID, Caroline Castera-Ducros <fnref n="1" />,<fnref n="2" />, Inès Jacquet <fnref n="1" />, Pascal Rathelot <fnref n="1" />,<fnref n="2" /> ID
and Patrice Vanelle <fnref n="1" />,<fnref n="2" />,* ID

**Abstract:** In continuation of our research program to develop original synthetic methods using TDAE methodology on nitroheterocyclic substrates, we were able to generate for the first time a stable carbanion in position 2 of the 5-nitroimidazole scaffold. Starting from a 2-chloromethyl-4-phenylsulfonylmethyl-5-nitroimidazole intermediate, prepared by the vicarious nucleophilic substitution of hydrogen (VNS) reaction, we selectively introduced a *N*-tosylbenzylimine moiety at position 2 without reducing the sulfone at position 4, leading to the formation of *N*-[[1-(2-chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl]ethyl]-4-methylbenzenesulfonamide in 47% yield. This new synthetic method using TDAE should allow access to new 2-substituted 5-nitroimidazole derivatives with various electrophiles such as carbonyls and other *N*-tosylbenzylimines.

**Keywords:** 5-nitroimidazole; *N*-tosylbenzylimine; tetrakis(dimethylamino)ethylene (TDAE); vicarious nucleophilic substitution (VNS)

1. Introduction

5-Nitroimidazoles are historically known for their antibacterial and anti-parasitic properties. Discovered in the 1960s [1], metronidazole (Figure 1) is still widely used for the treatment of parasitic infections caused by *Entamoeba histolytica* and *Giardia lamblia* [2] as well as infections caused by anaerobic bacteria such as *Bacteroides*, *Clostridioides* or *Helicobacter pylori* [3,4]. In 2019, fexinidazole (Figure 1) received marketing authorization as the first all-oral treatment against *Trypanosoma brucei gambiense* [5], renewing interest in the development of new nitroheterocycles active against kinetoplastid infections, such as leishmaniasis, sleeping sickness and Chagas disease. Thus, the development of original synthetic methods allowing the access to new 5-nitroimidazole derivatives is likely to be of interest for medicinal chemistry.

<figure><img src="image_3.png" /><figcaption>**Figure 1.** Structures of metronidazole and fexinidazole.</figcaption></figure>

<figure><img src="image_4.png" /></figure>

check for
updates

**Citation:** Paoli-Lombardo, R.; Primas, N.; Castera-Ducros, C.; Jacquet, I.; Rathelot, P.; Vanelle, P. N-[1-(2-Chlorophenyl)-2-[1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl]ethyl]-4-methylbenzenesulfonamide. *Molbank* 2023, 2023, M1633. https://doi.org/10.3390/M1633

Academic Editor: Fawaz Aldabbagh

Received: 31 March 2023

Revised: 19 April 2023

Accepted: 23 April 2023

Published: 25 April 2023

<figure><img src="image_5.png" /></figure>

**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1">1. CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France; romain.paoli-lombardo@etu.univ-amu.fr (R.P.-L.); caroline.ducros@univ-amu.fr (C.C.-D.); pascal.rathelot@univ-amu.fr (P.R.)</footnote>

<footnote n="2">2. Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital de la Conception, AP-HM, 13005 Marseille, France</footnote>

<footnote>* Correspondence: nicolas.primas@univ-amu.fr (N.P.); patrice.vanelle@univ-amu.fr (P.V.)</footnote>
Tetrakis(dimethylamino)ethylene (TDAE) is an organic reducing agent that has the specific property of activating the carbon-halogen bond to generate a carbanion [6]. Since 2002, our team has developed several reactions between nitroheterocyclic substrates and various electrophiles such as carbonyls and N-tosylbenzylimines using the TDAE methodology [7]. This strategy led to the synthesis of new 1,2-dimethyl-5-nitro-1H-imidazole derivatives bearing a phenyl or styryl group in position 4 (Scheme 1) [8,9].

<figure><img src="image_6.png" /><figcaption>**Scheme 1.** Preparation of 4-(4-substituted)styryl-1,2-dimethyl-5-nitro-1H-imidazole derivatives using TDAE.</figcaption></figure>

Based on previous work focused on the study of the vicarious nucleophilic substitution of hydrogen (VNS) reaction on the 5-nitroimidazole scaffold [10], our team also reported the synthesis of 2,4-disubstituted 5-nitroimidazole compounds using the VNS reaction to introduce a phenylsulfonylmethyl substituent at position 4. Some compounds showed potent antibacterial activity against *Clostridioides difficile* [11], while other compounds showed better antiparasitic activity than metronidazole and were associated with lower mutagenicity [12].

In continuation of this research program, we were able to generate for the first time a stable carbanion at position 2 of the 5-nitroimidazole scaffold using TDAE, which allowed us to introduce an N-tosylbenzylimine moiety at position 2 without reducing the sulfone at position 4.

## 2. Results

The 2-chloromethyl-4-phenylsulfonylmethyl-5-nitroimidazole intermediate (2) was obtained by vicarious nucleophilic substitution of hydrogen at position 4 of commercially available (1-methyl-5-nitro-1H-imidazol-2-yl)methanol (Scheme 2), followed by chlorination at position 2 with thionyl chloride [13,14].

<figure><img src="image_7.png" /><figcaption>**Scheme 2.** Synthesis of compounds 1 and 2.</figcaption></figure>

Reagents and conditions: (ii) Chloromethylsulfonylbenzene 2 equiv, tBuOK 4 equiv, DMF, -40 °C, 15 min, 40%; (iii) Thionyl chloride 2 equiv, CH₂Cl₂, 4 h, 67%.

Finally, the reaction of intermediate 2 with 1.5 equivalents of (E)-N-(2-chlorobenzylidene)-4-methylbenzenesulfonamide [15] in the presence of TDAE at -20 °C for 1 hour led to the desired compound 3 in moderate yield (Scheme 3).

<figure><img src="image_8.png" /><figcaption>**Scheme 3.** Synthesis of compound 3.</figcaption></figure>
Reagents and conditions: (iv) (E)-*N*-(2-Chlorobenzylidene)-4-methylbenzenesulfonamide 1.5 equiv, TDAE 1 equiv, DMF, N<sub>2</sub>, -20 °C, 1 h, 47%.

**3. Discussion**

Using our knowledge about the reactivity of activated chloromethyl groups in TDAE method-
ologies, we determined that the chloromethyl group at position 2 of a 4-phenylsulfonylmethyl-5-
nitroimidazole derivative could lead to a stable carbanion. Indeed, the electron withdraw-
ing effect (-M) of the nitro group at position 5 promotes the activation of the carbon-halogen
bond of the chloromethyl group in position 2 and the stabilization of the carbanion pro-
duced by TDAE.

This study reports on the first time that a stable carbanion has been generated at
position 2 of the 5-nitroimidazole scaffold. Moreover, mild conditions of the TDAE strategy
allowed us to specifically activate the carbon-chlorine bond at position 2 without reducing
the sulfone at position 4. This led to the introduction of a *N*-tosylbenzylimine moiety at
position 2 and the synthesis of compound **3** in moderate yield.

The development of this new synthetic method using TDAE should allow access to
new 2-substituted 5-nitroimidazole derivatives with various electrophiles such as carbonyls
and other *N*-tosylbenzylimines.

**4. Materials and Methods**

Melting points were determined on a Köfler melting point apparatus (Wagner & Munz GmbH, München, Germany) and were uncorrected. HRMS spectrum (ESI) was recorded on a SYNAPT G2 HDMS (Waters) at the Faculté des Sciences de Saint-Jérôme (Marseille). NMR spectra were recorded on a Bruker Avance 200 MHz or a Bruker Avance NEO 400 MHz NanoBay spectrometer at the Faculté de Pharmacie of Marseille. (¹H NMR: reference CDCl₃, δ = 7.26 ppm, reference DMSO-d₆, δ = 2.50 ppm and ¹³C NMR: reference CDCl₃, δ = 76.9 ppm, reference DMSO-d₆, δ = 39.52 ppm). The following adsorbent was used for column chromatography: silica gel 60 (Merck KGaA, Darmstadt, Germany, particle size 0.063–0.200 mm, 70–230 mesh ASTM). TLC was performed on 5 cm × 10 cm aluminum plates coated with silica gel 60F-254 (Merck) in an appropriate eluent. Visualization was performed with ultraviolet light (234 nm). The purity determination of synthesized compounds was checked by LC/MS analyses, which were realized at the Faculté de Pharmacie of Marseille with a Thermo Scientific Accela High-Speed LC System® (Waltham, MA, USA) coupled using a single quadrupole mass spectrometer Thermo MSQ Plus®. The purity of synthesized compound **3** was >95%. The RP-HPLC column is a Thermo Hypersil Gold® 50 × 2.1 mm (C₁₈ bounded), with particles of a diameter of 1.9 mm. The volume of the sample injected into the column was 1 µL. Chromatographic analysis, total duration of 8 min, was on the gradient of the following solvents: t = 0 min, methanol/water 50:50; 0 < t < 4 min, linear increase in the proportion of methanol to a methanol/water ratio of 95:5; 4 < t < 6 min, methanol/water 95:5; 6 < t < 7 min, linear decrease in the proportion of methanol to return to a methanol/water ratio of 50:50; 6 < t < 7 min, methanol/water 50:50. The water used was buffered with ammonium acetate 5 mM. The flow rate of the mobile phase was 0.3 mL/min. The retention times (tR) of the molecules analyzed were indicated in min. Reagents were purchased from Sigma-Aldrich or Fluorochem and used without further purification. Copies of ¹H NMR and ¹³C NMR are available in the Supplementary Materials.

4.1. {1-Methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}methanol (1)

To a solution of tBuOK (1.95 g, 17.4 mmol, 4 equiv) in dry DMF (15 mL) at -40 °C was added a solution of chloromethylsulfonylbenzene (1.66 g, 8.7 mmol, 2 equiv) in DMF (15 mL). Then, a solution of (1-methyl-5-nitro-1H-imidazol-2-yl)methanol (0.683 g, 4.35 mmol, 1 equiv.) was added dropwise and the reaction mixture was stirred at -40 °C for 15 min. A 2 M solution of HCl was added until pH 1 and the aqueous layer was extracted three times with ethyl acetate. Then, the organic layer was washed four times with brine,
dried over anhydrous Na₂SO₄, filtered and evaporated. Compound **1** was obtained after purification by chromatography on silica gel (eluent: cyclohexane-dichloromethane 2:8) as a yellow solid in 40% yield (0.541 g). mp 153 °C. ¹H NMR (250 MHz, DMSO-d₆) δ: 7.75-7.72 (m, 3H), 7.64-7.58 (m, 2H), 5.74 (brs, 1H), 4.91 (s, 2H), 4.53 (s, 2H), 3.87 (s, 3H). ¹³C NMR 63 MHz, DMSO-d₆) δ: 150.4, 138.9, 137.4, 134.2, 131.6, 129.4 (2C), 127.9 (2C), 55.9, 55.3, 34.1. LC/MS ESI+ tR 3.17, (m/z) [M + H]⁺ 312.07. HRMS (+ESI): 312.0646 [M + H]⁺. Calcd for C₁₂H₁₄N₃O₅S: 312.0649.

## 4.2. 2-(Chloromethyl)-1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazole (2)

To a solution of {1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}methanol (1) (0.5 g, 1.61 mmol, 1 equiv) in dichloromethane (15 mL) at 0 °C was added thionyl chloride (234 µL, 3.22 mmol, 2 equiv) and the reaction mixture was stirred at room temperature for 4 h. A 1 M K₂CO₃ solution was added to neutralize and the aqueous layer was extracted three times with dichloromethane. Then, the organic layer was washed four times with brine, dried over anhydrous Na₂SO₄, filtered and evaporated. Compound **2** was obtained after purification by chromatography on silica gel (eluent: petroleum ether-ethyl acetate 5:5) as a brown solid in 67% yield (0.354 g). mp 154 °C. ¹H NMR (250 MHz, CDCl₃) δ: 7.87-7.75 (m, 2H), 7.70-7.59 (m, 1H), 7.55-7.49 (m, 2H), 4.82 (s, 2H), 4.63 (s, 2H), 3.97 (s, 3H). ¹³C NMR 63 MHz, CDCl₃) δ: 145.9, 138.8, 137.9, 134.3, 132.4, 129.3 (2C), 128.4 (2C), 55.9, 40.0, 34.7. LC/MS ESI+ tR 4.28, (m/z) [M + H]⁺ 330.05/332.04. HRMS (+ESI): 330.0311 [M + H]⁺. Calcd for C₁₂H₁₃ClN₃O₄S: 330.0310.

## 4.3. N-[1-(2-Chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide (3)

To a solution of 2-(chloromethyl)-1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazole (2) (0.2 g, 0.61 mmol, 1 equiv.) in dry DMF (7 mL) at -20 °C was added (E)-N-(2-chlorobenzylidene)-4-methylbenzenesulfonamide (0.27 g, 0.92 mmol, 1.5 equiv). Then, tetrakis(dimethylamino)ethylene (142 µL, 0.61 mmol, 1 equiv) was added under N₂ atmosphere and the reaction mixture was stirred at -20 °C for 1 h. The mixture was slowly poured into an ice-water mixture, extracted three times with ethyl acetate. Then, the organic layer was washed four times with brine, dried over anhydrous Na₂SO₄, filtered and evaporated. Compound **3** was obtained after purification by chromatography on silica gel (eluent: dichloromethane) as a beige solid in 47% yield (0.17 g). mp 136 °C. ¹H NMR (400 MHz, DMSO-d₆) δ: 8.67 (d, *J* = 9.4 Hz, 1H), 7.79-7.66 (m, 3H), 7.66-7.55 (m, 3H), 7.39-7.33 (m, 3H), 7.33-7.21 (m, 2H), 7.14 (d, *J* = 8.1 Hz, 2H), 5.03 (ddd, *J* = 9.9, 9.4, 5.0 Hz, 1H), 4.80 (s, 2H), 3.64 (s, 3H), 2.99 (dd, *J* = 15.1, 9.9 Hz, 1H), 2.93 (dd, *J* = 15.1, 5.0 Hz, 1H), 2.26 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆) δ: 147.9, 142.3, 138.8, 138.0, 136.5, 134.0, 132.7, 130.9, 129.2 (3C), 129.1 (2C), 129.0 (2C), 128.2, 128.0 (2C), 127.6, 126.0 (2C), 55.3, 52.7, 34.0, 33.9, 20.8. LC/MS ESI+ tR 5.77, (m/z) [M + H]⁺ 588.82/590.85. HRMS (+ESI): 589.0978 [M + H]⁺. Calcd for C₂₆H₂₆ClN₄O₆S₂: 589.0977.

**Supplementary Materials:** The following supporting information can be downloaded online. Figure S1: ¹H NMR spectrum of compound **3**. Figure S2: ¹³C NMR spectrum of compound **3**.

**Author Contributions:** Conceptualization, N.P. and R.P.-L.; methodology, N.P.; validation, N.P.; formal analysis, R.P.-L.; investigation, R.P.-L. and I.J.; resources, P.V.; writing—original draft preparation, R.P.-L.; writing—review and editing, N.P., P.V., P.R. and C.C.-D.; supervision, N.P., P.V. and P.R.; project administration, N.P. and P.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by "Aix-Marseille Université (AMU)", by "Centre national de la recherche scientifique (CNRS)" and by "Assistance publique-Hôpitaux de Marseille (AP-HM)".

**Data Availability Statement:** Not applicable.
**Acknowledgments:** We want to thank Vincent Remusat (Institut de Chimie Radicaire, Marseille) for his help with NMR analysis, Valérie Monnier and Gaëlle Hisler (Spectropole, Marseille) for performing HRMS analysis.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Durel, P.; Couture, J.; Collart, P.; Girot, C. Flagyl (Metronidazole). *Sex. Transm. Infect.* **1960**, *36*, 154–157. [CrossRef] [PubMed]

2. Cohen, J. Metronidazole to Clear Intestinal Parasites. *Lancet* **1996**, *348*, 273. [CrossRef] [PubMed]

3. Brogden, R.N.; Heel, R.C.; Speight, T.M.; Avery, G.S. Metronidazole in Anaerobic Infections: A Review of Its Activity, Pharmacokinetics and Therapeutic Use. *Drugs* **1978**, *16*, 387–417. [CrossRef] [PubMed]

4. Löfmark, S.; Edlund, C.; Nord, C.E. Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections. *Clin. Infect. Dis.* **2010**, *50*, S16–S23. [CrossRef] [PubMed]

5. Pelfrene, E.; Harvey Allchurch, M.; Ntamabyaliro, N.; Nambasa, V.; Ventura, F.V.; Nagercoil, N.; Cavaleri, M. The European Medicines Agency's Scientific Opinion on Oral Fexinidazole for Human African Trypanosomiasis. *PLoS Negl. Trop. Dis.* **2019**, *13*, e0007381. [CrossRef] [PubMed]

6. Burkholder, C.; Dolbier, W.R.; Medebielle, M.; Ndedi, A. Tetrakis (Dimethylamino) Ethylene (TDAE) as a Useful Reductant of Some Chlorodifluoromethylated Ketones. A New Approach for the Synthesis of α,α-Difluoroketone Derivatives. *Tetrahedron Lett.* **1998**, *39*, 8853–8856. [CrossRef]

7. Giuglio-Tonolo, G.; Terme, T.; Médebielle, M.; Vanelle, P. Original Reaction of P-Nitrobenzyl Chloride with Aldehydes Using Tetrakis (Dimethylamino) Ethylene (TDAE). *Tetrahedron Lett.* **2003**, *44*, 6433–6435. [CrossRef]

8. Crozet, M.; Terme, T.; Vanelle, P. Designing New 5-Nitroimidazoles: Towards Safer Anti-Infectious Agents. *Lett. Drug Des. Discov.* **2013**, *11*, 531–559. [CrossRef]

9. Primas, N.; Neildé, K.; Kabri, Y.; Crozet, M.; Terme, T.; Vanelle, P. Exploring the Synthesis and the Reactivity of 4-[4-(chloromethyl) Styryl]-1,2-Dimethyl-5-Nitro-1H-Imidazole in TDAE Strategy. *Synthesis* **2013**, *46*, 348–356. [CrossRef]

10. Makosza, M.; Kwast, E. Vicarious Nucleophilic Substitution of Hydrogen in Imidazole Derivatives. *Bull. Pol. Acad. Sci. Chem.* **1987**, *35*, 287–292.

11. Spitz, C.; Mathias, F.; Péchiné, S.; Doan, T.H.D.; Innocent, J.; Pellissier, S.; Di Giorgio, C.; Crozet, M.D.; Janoir, C.; Vanelle, P. 2,4-Disubstituted 5-Nitroimidazoles Potent against Clostridium Difficile. *ChemMedChem* **2019**, *14*, 561–569. [CrossRef] [PubMed]

12. Crozet, M.D.; Botta, C.; Gasquet, M.; Curti, C.; Rémusat, V.; Hutter, S.; Chapelle, O.; Azas, N.; De Méo, M.; Vanelle, P. Lowering of 5-Nitroimidazole's Mutagenicity: Towards Optimal Antiparasitic Pharmacophore. *Eur. J. Med. Chem.* **2009**, *44*, 653–659. [CrossRef] [PubMed]

13. Makosza, M.; Winiarski, J. Vicarious Nucleophilic Substitution of Hydrogen. *Acc. Chem. Res.* **1987**, *20*, 282–289. [CrossRef]

14. Makosza, M.; Wojciechowski, K. Nucleophilic Substitution of Hydrogen in Heterocyclic Chemistry. *Chem. Rev.* **2004**, *104*, 2631–2666. [CrossRef] [PubMed]

15. Sharghi, H.; Hosseini-Sarvari, M.; Ebrahimpourmoghaddam, S. A Novel Method for the Synthesis of N-Sulfonyl Aldimines Using AlCl3 under Solvent-Free Conditions (SFC). *Arkivoc* **2007**, *2007*, 255–264. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.